Holen Sie sich die Stockscreener-App
63.08
2.19%
-1.41
Handel nachbörslich:
64.34
1.26
+2.00%
Schlusskurs vom Vortag:
$64.49
Offen:
$64.56
24-Stunden-Volumen:
1.54M
Relative Volume:
0.84
Marktkapitalisierung:
$7.47B
Einnahmen:
$1.40B
Nettoeinkommen (Verlust:
$316.89M
KGV:
25.32
EPS:
2.4918
Netto-Cashflow:
$644.59M
1W Leistung:
+1.53%
1M Leistung:
-6.37%
6M Leistung:
-5.81%
1J Leistung:
+5.54%
1-Tages-Spanne:
$62.69
$64.69
1-Wochen-Bereich:
$62.69
$66.00
52-Wochen-Spanne:
$47.50
$82.22
Halozyme Therapeutics Inc Stock (HALO) Company Profile
Firmenname
Halozyme Therapeutics Inc
Sektor
Branche
Telefon
(858) 794-8889
Adresse
12390 EL CAMINO REAL, SAN DIEGO, CA
Compare HALO vs VRTX, REGN, ARGX, ALNY, INSM
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
HALO
Halozyme Therapeutics Inc
|
63.08 | 7.64B | 1.40B | 316.89M | 644.59M | 2.4918 |
VRTX
Vertex Pharmaceuticals Inc
|
434.30 | 111.45B | 12.07B | 3.95B | 3.19B | 15.33 |
REGN
Regeneron Pharmaceuticals Inc
|
763.04 | 80.54B | 14.34B | 4.50B | 3.77B | 41.56 |
ARGX
Argen X Se Adr
|
748.25 | 46.32B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
330.34 | 42.29B | 3.71B | 313.75M | 465.38M | 2.2571 |
INSM
Insmed Inc
|
163.81 | 35.01B | 606.42M | -1.28B | -997.58M | -6.403 |
Halozyme Therapeutics Inc Stock (HALO) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-12-04 | Herabstufung | Goldman | Neutral → Sell |
| 2025-10-14 | Hochstufung | Leerink Partners | Underperform → Market Perform |
| 2025-08-06 | Hochstufung | Morgan Stanley | Equal-Weight → Overweight |
| 2025-07-10 | Fortgesetzt | Goldman | Neutral |
| 2025-05-14 | Herabstufung | Morgan Stanley | Overweight → Equal-Weight |
| 2025-05-13 | Herabstufung | Leerink Partners | Market Perform → Underperform |
| 2024-10-07 | Herabstufung | Wells Fargo | Overweight → Equal Weight |
| 2024-09-19 | Herabstufung | JP Morgan | Overweight → Neutral |
| 2024-06-07 | Herabstufung | Piper Sandler | Overweight → Neutral |
| 2024-02-29 | Eingeleitet | TD Cowen | Outperform |
| 2023-07-24 | Herabstufung | Goldman | Buy → Neutral |
| 2023-07-24 | Eingeleitet | H.C. Wainwright | Buy |
| 2023-05-10 | Hochstufung | Piper Sandler | Neutral → Overweight |
| 2023-03-27 | Fortgesetzt | Berenberg | Buy |
| 2023-03-16 | Herabstufung | SVB Securities | Outperform → Market Perform |
| 2022-12-21 | Fortgesetzt | Morgan Stanley | Overweight |
| 2022-11-28 | Eingeleitet | Wells Fargo | Overweight |
| 2022-09-09 | Eingeleitet | Morgan Stanley | Overweight |
| 2022-05-23 | Eingeleitet | SVB Leerink | Outperform |
| 2021-06-14 | Eingeleitet | Evercore ISI | Outperform |
| 2021-05-17 | Eingeleitet | SVB Leerink | Outperform |
| 2021-05-11 | Herabstufung | Piper Sandler | Overweight → Neutral |
| 2021-01-21 | Bestätigt | The Benchmark Company | Buy |
| 2020-12-17 | Eingeleitet | Berenberg | Buy |
| 2020-09-14 | Fortgesetzt | JP Morgan | Overweight |
| 2020-07-01 | Eingeleitet | The Benchmark Company | Buy |
| 2020-02-05 | Hochstufung | Piper Sandler | Neutral → Overweight |
| 2020-01-09 | Hochstufung | BMO Capital Markets | Market Perform → Outperform |
| 2020-01-08 | Eingeleitet | Goldman | Buy |
| 2019-11-05 | Hochstufung | Barclays | Underweight → Equal Weight |
| 2018-10-19 | Fortgesetzt | Piper Jaffray | Neutral |
| 2018-05-11 | Herabstufung | Barclays | Equal Weight → Underweight |
| 2018-01-24 | Eingeleitet | Goldman | Neutral |
| 2017-10-16 | Bestätigt | Piper Jaffray | Overweight |
| 2017-01-06 | Herabstufung | Citigroup | Buy → Neutral |
| 2016-11-03 | Eingeleitet | Deutsche Bank | Buy |
| 2015-12-04 | Eingeleitet | Wells Fargo | Outperform |
| 2015-11-18 | Eingeleitet | Citigroup | Buy |
| 2015-09-22 | Eingeleitet | Barclays | Overweight |
| 2015-06-22 | Bestätigt | JP Morgan | Overweight |
| 2015-03-03 | Bestätigt | UBS | Buy |
| 2015-02-18 | Bestätigt | MLV & Co | Buy |
| 2015-01-08 | Bestätigt | MLV & Co | Buy |
Alle ansehen
Halozyme Therapeutics Inc Aktie (HALO) Neueste Nachrichten
Halozyme Therapeutics (HALO) appoints interim CFO amid growth plans - MSN
Halozyme Therapeutics Insider Sold Shares Worth $2,592,237, According to a Recent SEC Filing - marketscreener.com
Halozyme Therapeutics, Inc. (HALO) stock price, news, quote and history - Yahoo Finance Singapore
Halozyme Therapeutics, Inc. (HALO) Stock Price, News, Quote & History - Yahoo! Finance Canada
How The Investment Story Is Shifting For Halozyme Therapeutics (HALO) After Recent Analyst Calls - Yahoo Finance
Element Squared LLC Invests $1.19 Million in Halozyme Therapeutics, Inc. $HALO - marketbeat.com
Hedge Fund and Insider Trading News: Warren Buffett, George Soros, Steve Cohen, Ken Griffin, Brevan Howard, Tudor Investment Corp, L.B. Foster (FSTR), Halozyme Therapeutics Inc (HALO), and More - Insider Monkey
Tema Etfs LLC Invests $1.7M in Halozyme Therapeutics - National Today
Tema Etfs LLC Makes New $1.70 Million Investment in Halozyme Therapeutics, Inc. $HALO - marketbeat.com
Halozyme Therapeutics CEO sells $2.59 million in stock By Investing.com - Investing.com Canada
Insider Selling: Halozyme Therapeutics (NASDAQ:HALO) CEO Sells 20,000 Shares of Stock - marketbeat.com
Halozyme (NASDAQ: HALO) grants 10,000 RSUs to interim CFO Ramsay - stocktitan.net
Halozyme (NASDAQ: HALO) CEO exercises 40k options, sells 40k shares - stocktitan.net
HALO Stock Price, Quote & Chart | HALOZYME THERAPEUTICS INC (NASDAQ:HALO) - ChartMill
HALOZYME THERAPEUTICS Accounts Payable & Accrued Expense: $1 - GuruFocus
Is Halozyme Therapeutics (HALO) Pricing Reflect Its Potential After Recent Share Price Pullback - Sahm
Halozyme Therapeutics Experiences Revision in Stock Evaluation Amid Market Volatility - Markets Mojo
Halozyme Therapeutics (HALO) Appoints Interim CFO Amid Growth Plans - Insider Monkey
Halozyme to Report Second Quarter 2025 Financial and Operating Results - Quantisnow
Record revenue and royalties fail to lift Halozyme Therapeutics stock amid sustained technical weakness - Traders Union
Sell Signal: Will Halozyme Therapeutics Inc announce a stock split2026 Sentiment & Proven Capital Preservation Methods - baoquankhu1.vn
Assenagon Asset Management Acquires Stake in Halozyme Therapeutics - National Today
Assenagon Asset Management S.A. Takes Position in Halozyme Therapeutics, Inc. $HALO - MarketBeat
Halozyme (HALO) loses 9% on weak earnings - MSN
Halozyme Therapeutics Inc Stock Historical Valuations | HAM:RV7 - GuruFocus
Halozyme Therapeutics Inc Stock Intrinsic Values - GuruFocus
5 Most Undervalued Growth Stocks to Buy According to Analysts - Insider Monkey
HALO (Halozyme Therapeutics) Cash Receipts from Loans - GuruFocus
Why is Halozyme Therapeutics (HALO) down 13.1% since last earnings report? - MSN
HALO (Halozyme Therapeutics) Cash Receipts from Tax Refunds - GuruFocus
Halozyme Therapeutics prices $1.3 billion convertible notes - MSN
Vanguard realignment reports zero Halozyme holdings (NASDAQ: HALO) - Stock Titan
HALO Stock Chart | HALOZYME THERAPEUTICS INC (NASDAQ:HALO) - ChartMill
Is Halozyme’s Interim CFO Appointment Shaping The ENHANZE Royalty Story For Halozyme Therapeutics (HALO)? - simplywall.st
Unpacking Q4 Earnings: Halozyme Therapeutics (NASDAQ:HALO) In The Context Of Other Therapeutics Stocks - Yahoo Finance
Halozyme declines after Q4 bottom line miss, reiterates 2026 guidance - MSN
Congress Asset Management Co. Cuts Stake in Halozyme Therapeutics - National Today
Congress Asset Management Co. Cuts Position in Halozyme Therapeutics, Inc. $HALO - MarketBeat
Interim CFO at Halozyme (NASDAQ: HALO) files initial Form 3 ownership - Stock Titan
HALOZYME THERAPEUTICS, INC. ($HALO) President and CEO 2025 Pay Revealed - Quiver Quantitative
[ARS] HALOZYME THERAPEUTICS, INC. SEC Filing - Stock Titan
Executive pay, board elections lead Halozyme (NASDAQ: HALO) 2026 proxy - Stock Titan
Halozyme appoints David Ramsay as interim CFO - MSN
Moving Averages: Will Halozyme Therapeutics Inc benefit from seasonality2026 Buyback Activity & Proven Capital Preservation Methods - baoquankhu1.vn
Halozyme Therapeutics, Inc. Experiences Revision in Its Stock Evaluation Amid Mixed Performance Metrics - Markets Mojo
Halozyme Therapeutics, Inc. $HALO Shares Purchased by Allworth Financial LP - MarketBeat
Halozyme Touts $1.8B Revenue Outlook, Expanding Subcutaneous Drug Delivery - National Today
Acumen Pharmaceuticals to Report Fourth Quarter and Year-End 2025 Financial Results on March 26, 2026 - GlobeNewswire Inc.
What Has Caused Halozyme Therapeutics (HALO) Shares to Fall 13.1% Following Its Most Recent Earnings Report? - Bitget
Why Is Halozyme Therapeutics (HALO) Down 13.1% Since Last Earnings Report? - Yahoo Finance
Halozyme Therapeutics : ESG Key Data & Metrics (rev11 Halozyme ESG Key Data 2026 ISS Corporate comments Mar2026 version 1 for publication) - marketscreener.com
Finanzdaten der Halozyme Therapeutics Inc-Aktie (HALO)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.87%
0.11%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):